Research Analysts Issue Forecasts for Valneva Q3 Earnings

Valneva SE Sponsored ADR (NASDAQ:VALN) – Equities researchers at HC Wainwright boosted their Q3 2026 earnings per share estimates for Valneva in a research report issued on Friday, August 14th. HC Wainwright analyst B. Folkes now anticipates that the company will earn ($0.18) per share for the quarter, up from their previous forecast of ($0.21). The consensus estimate for Valneva’s current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Valneva’s Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($1.04) EPS, FY2027 earnings at $1.80 EPS, FY2028 earnings at $2.12 EPS, FY2029 earnings at $2.26 EPS and FY2030 earnings at $3.94 EPS.

VALN has been the subject of several other reports. TD Cowen began coverage on Valneva in a research note on Tuesday, August 11th. They issued a “buy” rating and a $12.00 target price for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Valneva in a report on Thursday, June 18th. Wall Street Zen upgraded Valneva from a “strong sell” rating to a “sell” rating in a research report on Monday, June 1st. Finally, The Goldman Sachs Group cut Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price objective for the company. in a report on Wednesday, April 22nd. Four analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, Valneva presently has an average rating of “Hold” and an average target price of $11.98.

Valneva Stock Performance

Shares of Valneva stock opened at $7.06 on Tuesday. The company has a debt-to-equity ratio of 2.04, a current ratio of 2.16 and a quick ratio of 1.69. The firm has a 50 day simple moving average of $5.28 and a 200 day simple moving average of $6.89. Valneva has a fifty-two week low of $4.75 and a fifty-two week high of $12.25. The firm has a market cap of $669.92 million, a P/E ratio of -3.35 and a beta of 1.77.

Valneva (NASDAQ:VALN) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.21). Valneva had a negative net margin of 110.33% and a negative return on equity of 153.20%. The company had revenue of $39.37 million during the quarter, compared to analyst estimates of $44.17 million.

Hedge Funds Weigh In On Valneva

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VALN. China Universal Asset Management Co. Ltd. acquired a new stake in Valneva in the 4th quarter valued at $44,000. JPMorgan Chase & Co. bought a new stake in shares of Valneva during the third quarter worth approximately $124,000. XTX Topco Ltd acquired a new stake in shares of Valneva during the fourth quarter worth $94,000. Finally, Marex Group plc acquired a new position in shares of Valneva in the second quarter valued at about $64,000. Institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.